Patents by Inventor Anna Avino

Anna Avino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sphingosine-bound siRNA
    Patent number: 8703731
    Abstract: The invention relates to novel oligomer analogues and their use in oligonucleotide-based therapies. More specifically, the invention concerns oligonucleotides carrying lipid molecules and their use as potential inhibitors of gene expression.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: April 22, 2014
    Assignee: Sylentis S.A.U.
    Inventors: Ana Isabel Jimenez, Gema Panizo, Tamara Martinez, Anna Avino, Clara Caminal, Ramon Eritja, Santiago Grijalvo
  • Sphingosine-bound siRNA
    Publication number: 20120142765
    Abstract: The invention relates to novel oligomer analogues and their use in oligonucleotide-based therapies. More specifically, the invention concerns oligonucleotides carrying lipid molecules and their use as potential inhibitors of gene expression.
    Type: Application
    Filed: June 22, 2010
    Publication date: June 7, 2012
    Applicant: Sylentis S.A.U.
    Inventors: Ana Isabel Jimenez, Gema Panizo, Tamara Martinez, Anna Avino, Clara Caminal, Ramon Eritja, Santiago Grijalvo
  • Triplex-forming oligonucleotides containing modified purines and their applications
    Publication number: 20050014164
    Abstract: This invention presents oligonucleotide derivatives comprising a complementary purine part carrying one or more 8-aminopurines such as 8-aminoadenine, 8-aminoguanine and 8-aminohypoxanthine connected with a linker to an oligonucleotide carrying either GT or GA sequences. These oligonucleotide derivatives bind polypyrimidine sequences complementary (in the antiparallel sense) to the purine part by formation of purine-purine-pyrimidine triple helices. The oligonucleotides carrying 8-aminoguanines described in this invention have better binding properties than unmodified oligonucleotides. This enhancement in stability, coupled with the lack of an acidic pH requirement, makes the oligonucleotides carrying 8-aminopurines effective in applications involving oligonucleotide targeting of single stranded RNA in vitro and in vivo, as well as applications requiring triple helix formation.
    Type: Application
    Filed: October 21, 2003
    Publication date: January 20, 2005
    Inventors: Ramon Eritja, Anna Avino